Merck & Company Inc - Asset Resilience Ratio
Merck & Company Inc (MRK) has an Asset Resilience Ratio of 0.29% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Merck & Company Inc's Asset Resilience Ratio has changed over time. Check MRK strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Merck & Company Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Merck & Company Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $375.00 Million | 0.29% |
| Total Liquid Assets | $375.00 Million | 0.29% |
Asset Resilience Insights
- Limited Liquidity: Merck & Company Inc maintains only 0.29% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Merck & Company Inc Industry Peers by Asset Resilience Ratio
Compare Merck & Company Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AstraZeneca PLC
NYSE:AZN |
Drug Manufacturers - General | 0.10% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 7.83% |
|
AstraZeneca PLC
F:ZEGA |
Drug Manufacturers - General | 0.03% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 8.63% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.48% |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436 |
Drug Manufacturers - General | 17.40% |
|
Sichuan Kelun Pharmaceutical Co Ltd
SHE:002422 |
Drug Manufacturers - General | 4.41% |
Annual Asset Resilience Ratio for Merck & Company Inc (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Merck & Company Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.64% | $14.56 Billion | $136.87 Billion | -1.05pp |
| 2024-12-31 | 11.69% | $13.69 Billion | $117.11 Billion | +5.04pp |
| 2023-12-31 | 6.65% | $7.09 Billion | $106.67 Billion | -5.44pp |
| 2022-12-31 | 12.09% | $13.19 Billion | $109.16 Billion | +4.43pp |
| 2021-12-31 | 7.66% | $8.10 Billion | $105.69 Billion | -1.14pp |
| 2020-12-31 | 8.80% | $8.06 Billion | $91.59 Billion | -3.58pp |
| 2019-12-31 | 12.38% | $10.45 Billion | $84.40 Billion | +1.66pp |
| 2018-12-31 | 10.73% | $8.86 Billion | $82.64 Billion | +1.06pp |
| 2017-12-31 | 9.67% | $8.50 Billion | $87.87 Billion | -5.37pp |
| 2016-12-31 | 15.04% | $14.34 Billion | $95.38 Billion | +10.21pp |
| 2015-12-31 | 4.82% | $4.90 Billion | $101.68 Billion | -3.61pp |
| 2014-12-31 | 8.43% | $8.28 Billion | $98.17 Billion | +6.67pp |
| 2013-12-31 | 1.77% | $1.86 Billion | $105.64 Billion | -0.77pp |
| 2012-12-31 | 2.53% | $2.69 Billion | $106.13 Billion | +1.16pp |
| 2011-12-31 | 1.37% | $1.44 Billion | $105.13 Billion | +0.14pp |
| 2010-12-31 | 1.23% | $1.30 Billion | $105.78 Billion | +0.97pp |
| 2009-12-31 | 0.26% | $293.00 Million | $112.31 Billion | -2.11pp |
| 2008-12-31 | 2.37% | $1.12 Billion | $47.20 Billion | -3.62pp |
| 2007-12-31 | 5.99% | $2.89 Billion | $48.35 Billion | -0.29pp |
| 2006-12-31 | 6.28% | $2.80 Billion | $44.57 Billion | -7.22pp |
| 2005-12-31 | 13.50% | $6.05 Billion | $44.85 Billion | +3.60pp |
| 2004-12-31 | 9.89% | $4.21 Billion | $42.57 Billion | +2.57pp |
| 2003-12-31 | 7.32% | $2.97 Billion | $40.59 Billion | +1.59pp |
| 2002-12-31 | 5.74% | $2.73 Billion | $47.56 Billion | +3.14pp |
| 2001-12-31 | 2.60% | $1.14 Billion | $44.02 Billion | -1.71pp |
| 2000-12-31 | 4.30% | $1.72 Billion | $39.91 Billion | +0.99pp |
| 1999-12-31 | 3.31% | $1.18 Billion | $35.63 Billion | -- |
About Merck & Company Inc
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, a… Read more